The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.32% | -2.42% | 13.72% | 18.63% | 11.81% | N/A | N/A | N/A | N/A | N/A | 6.61% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.32% | -2.42% | 13.72% | 18.63% | 11.81% | N/A | N/A | N/A | N/A | N/A | 12.7% |
| Rank within category | 7/19 | 7/18 | 3/18 | 3/18 | 3/17 | N/A | N/A | N/A | N/A | N/A | N/A |
| Sector Funds | 2024 | 2025 | 2026 |
|---|---|---|---|
| Yearly returns | N/A | -2.67% | 14.53% |
| Q1 returns | N/A | -7.32% | -2.64% |
| Q2 returns | N/A | 5.55% | 18.06% |
| Q3 returns | N/A | -3.44% | 4.95% |
| Q4 returns | N/A | 3.04% | -5.05% |
0.50% on or before 90D, Nil after 90D
| Alpha | 0.760356 |
| Beta | 0.5843 |
| Sharpe Ratio | 0.102729 |
| Sortino Ratio | 0.204004 |
| R-Squared | 0.2591 |
| Tracking Error | 3.8398 |
| Downside Risk | 15.469 |
| Std. Deviation (Annualised) | 14.248 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| PGIM India Healthcare Fund - Regular Plan - Growth Current | -7.32% | -2.42% | 13.72% | 18.63% | 11.81% | N/A | N/A | N/A | 6.61% | 130.33 | 2.61 | 0.10 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.36% |
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.25% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.49% |
| Clearing Corporation of India Ltd. | Cash & Cash Equivalents and Net Assets | 5.24% | |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.96% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 4.71% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 4.33% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.04% |
| Manipal Health Enterprises Ltd. | Healthcare Services | Domestic Equities | 3.68% |
| Navin Fluorine International Ltd. | Chemicals & Petrochemicals | Domestic Equities | 3.24% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.12% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 2.99% |
| Rubicon Research Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.99% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.91% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 2.56% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.54% |
| ICICI Lombard General Insurance Company Ltd. | Insurance | Domestic Equities | 2.10% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.04% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.04% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.93% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.92% |
| Dr Agarwals Eye Hospital Ltd. | Healthcare Services | Domestic Equities | 1.86% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.81% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 1.52% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.50% |
| Jupiter Life Line Hospitals Ltd. | Healthcare Services | Domestic Equities | 1.46% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.46% |
| Symbiotec Pharmalab Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.10% |
| Lenskart Solutions Ltd. | Retailing | Domestic Equities | 0.99% |
| Molbio Diagnostics Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.80% |
| Orchid Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.79% |
| Sagility Ltd. | IT - Services | Domestic Equities | 0.40% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | -0.11% | |
| Total | 100.00% | ||
Mr. Puneet Pal has over 10 years of experience in asset management. In his position as Head of Fixed Income, Puneet is an integral part of a team of investment professionals managing Fixed Income funds for BNP Paribas Mutual Fund. In his previous assignment, he was Senior Vice President & Fund Manager at UTI Mutual Fund from July 2008 - February 15, 2012. Puneet was a Fund Manager at Tata Mutual Fund (August 2006 - July 2008) before which he was with UTI Mutual Fund for 3 years.
March 2019 onwards: AVP- Research with PGIM India Asset Management Pvt LtdMay 2018 to March 2019: Senior Research Analyst with Renaissance Investment Managers Private LimitedSeptember 2009 to May 2018: With Canara Robeco AMC Ltd. - Last Position Held - Equity Research Analyst
Collectively over 15 years of experience in Indian financial markets, primarily in equity research.
Over 13 years of experience in Equity market, research and fund management.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
